Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Critical Diagnostics signs agreements with four new European distributors

Critical Diagnostics, a U.S.-based biomarker company focused on cardiovascular diseases, today announced that it has signed agreements with four new European distributors in Germany, Spain, France and Turkey.

15 Oct 2012

Pioneering research paves way for new treatments for pulmonary arterial hypertension

Pioneering research conducted by the University of Sheffield is paving the way for new treatments which could benefit patients suffering from the fatal lung disease pulmonary arterial hypertension (PAH).

15 Oct 2012

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

15 Oct 2012

Neurotensin as an indicator for poor health outcomes in women

The satiety hormone neurotensin may provide a novel biomarker for assessing risk for diabetes, cardiovascular disease, and breast cancer among women, report researchers.

12 Oct 2012

Clinical study to investigate Cytori's adipose-derived cell therapy in patients with heart failure

Timothy Henry, M.D. of the Minneapolis Heart Institute Foundation treated the first patient in the ATHENA study, injecting the patient's own stem cells into the heart to restore blood flow and help regenerate heart muscle. Henry, the Foundation's Director of Research is co-principal investigator of the ATHENA study sponsored by Cytori Therapeutics.

12 Oct 2012

Study shows how CaM kinase II triggers cell death following heart damage

University of Iowa researchers have previously shown that an enzyme called CaM kinase II plays a pivotal role in the death of heart cells following a heart attack or other conditions that damage or stress heart muscle.

11 Oct 2012

S100A1 protein critical for endothelial cell function in ischemic angiogenesis

Restoring diminished levels of a protein shown to prevent and reverse heart failure damage could also have therapeutic applications for patients with critical limb ischemia (CLI), suggests a new preclinical study published online October 9 in Circulation Research from researchers at the Center for Translational Medicine at Thomas Jefferson University.

11 Oct 2012

Decrease in doctor appointments, preventable hospital visits draw scrutiny

Medpage Today offers a pair of stories exploring Census findings regarding doctor visits in 2010 as well as MedPAC's interest in "preventable" hospital visits.

10 Oct 2012

Navigating the Labyrinth of Traumatic Brain Injury to Discover a Secondary Neurological Condition

Working with individuals with traumatic brain injury (TBI) every day, I see the debilitating effects and long-term struggles firsthand.

9 Oct 2012

Medicaid news: Florida program caught between feds and state efforts; Ark. begins new payment plans for doctors

The Department of Health and Human Services and Florida officials negotiate changes to the state's Medicaid plan. In the meantime, Arkansas doctors offer a cautious endorsement as the state tries "episodic" payments for some common conditions.

9 Oct 2012

NovaSom launches full-service testing program for pre-operative diagnosis of OSA

NovaSom, Inc., the leader in home sleep testing and cost-saving solutions for Obstructive Sleep Apnea (OSA) management, today announces the launch of AccuSom Safe Recovery.

8 Oct 2012

Trevena reports completion of TRV027 Phase 2a study in advanced heart failure patients

Trevena, Inc., the leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, today announced that it has successfully completed a Phase 2a study on the hemodynamic effects of TRV027 in patients with advanced heart failure with reduced ejection fraction.

8 Oct 2012